Reference
  1. Ueng KC, Lin MC, Chan KC, Lin CS. Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):769-80. DOI: 10.1517/17425255.3.5.769.
  2. Noda T, Yaginuma T, O’Rourke MF, Hosoda S. Effects of nifedipine on systemic and pulmonary vascular impedance in subjects undergoing cardiac catheterization. Hypertens Res. 2006 Jul;29(7):505-13. doi: 10.1291/hypres.29.505. PMID: 17044663.
  3. Di Filippo C, Lampa E, Forgione A,et al. Effects of nifedipine controlled release on blood pressure and heart rate of spontaneously hypertensive rats. Comparison with nifedipine standard and with amlodipine [J].Ital Heart J Suppl,2005,6(5):285-290.
  4. Jiang S. T., Yu S. Y. Efficacy of nifedipine extended-release tablets in the treatment of hypertension combined with diabetes mellitus [J]. Shandong Medicine, 2010,50(21):67-68.
  5. Murdoch D, Brogden RN. Sustained release nifedipine formulations; an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991; 41 (5): 737-79
  6. Ruzicka M, Leenen FH. Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996; 9: 86–94.
  7. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 6: 886–93.
  8. Cohn JN. Sympathetic nervous system activity and the heart. Am J Hypertens 1989; 2: 353S–356S.
  9. Tang Shude, Gong Lansheng. Pharmacodynamics and pharmacokinetics of nifedipine controlled-release tablets[J]. Shanghai Medicine, 1997(01):23-24.
  10. PHYSICIAN’S DESK REFERENCE:Product Information,Pfizer,Inc.Procardia® capsules and Procardia XL®.Thomson Healthcare, Montvale,NJ 2002).
  11. Feng L, Hou Hsiao Y, Meng L, et al. Application of drug utilization analysis of cardiovascular system in 157 hospitals in Yangtze River basin in 2005[J]. Chinese Journal of New Drugs and Clinics, 2007, 26(3):175
  12. Chen Biao, Wu Shu Yue, Wang Yan Ning, et al. Case analysis of severe adverse reactions caused by short-acting nifedipine[J]. Chinese Pharmacist,2009,12(8):1136-1137.
  13. Tang Shude, Gong Lansheng. Pharmacodynamics and pharmacokinetics of nifedipine controlled-release tablets[J]. Shanghai Medicine, 1997(01):23-24.
  14. Li JF, Yan L, Wang XF, Li XT, Zhang SJ, Zhang LR. Effects of high-fat diet and ABCB1 gene polymorphisms on the pharmacokinetics of nifedipine in healthy subjects. Chinese Journal of Pharmacology,2014,30(04):566-569.
  15. Schuger, B., Brendel, E., Werneman, et al. Dose-related food interactions observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Euro J Clin Pharmacol 58, 119-125 (2002)
Table 1. Pharmacokinetic Parameters of nifedipine Test (T) and Reference (R) Formulations.